Protocol Ledger

NCT04162899 · Phase II · COMPLETED

A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis

Interventional Phase II clinical trial protocol NCT04162899 sponsored by Reistone Biopharma Company Limited in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-11-06 Enrollment: 105 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04162899
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)105 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04162899
Protocol FieldVerified Registry Value
NCT IdentifierNCT04162899
Consolidated Lead SponsorReistone Biopharma Company Limited
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment105 participants (ACTUAL)
Registered Start Date2019-11-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI